TrimRX Program Review: Physician-Directed GLP-1 Weight Loss, All From Home TrimRX is a physician-directed telehealth program designed to help adults throughout the U.S
It'll catch up, but rushing it won't help
In certain cancers, the methylation of CpG islands in the promoter region of the SOCS1 gene inactivates the gene
SUSTAIN 6 was time and eventdriven (104 weeks exposure and 122 primary outcome events),32 whereas PIONEER 6 was solely eventdriven (122 primary outcome events).33 SUSTAIN 6 was a fourarmed trial (semaglutide 0.5 mg and 1.0 mg once weekly, and volumematched placebo), with the primary analysis performed on pooled semaglutide and placebo groups,32 whereas PIONEER 6 was a twoarmed trial (oral semaglutide target dose 14 mg once daily and placebo).33 The primary outcome in both trials was the time to first occurrence of a threecomponent MACE (CV death, nonfatal myocardial infarction [MI], or nonfatal stroke).32 There were fewer MACE with semaglutide versus placebo in both trials: the hazard ratios (HRs) for SUSTAIN 6 and PIONEER 6 were 0.74 (95% confidence interval [CI] 0.58, 0.95) and 0.79 (0.57, 1.11), respectively.32, 33 In SUSTAIN 6, the results were significant for noninferiority and superiority, although the latter was not prespecified.32 SUSTAIN 6 and PIONEER 6 aimed to rule out an excess risk of CV events with semaglutide versus placebo, defined by the US Food and Drug Administration as having an upper bound of the 95% CI 0.05), suggesting no heterogeneity in the treatment effects across these subgroups
